Havrix 1440: Anwendung, Dosierung & Nebenwirkungen – Alles, was Sie wissen müssen

Havrix: 1 mL IM followed by a 1 mL booster dose 6 to 12 months following primary immunization. Primary immunization is recommended at least 2 weeks before expected exposure to hepatitis A virus. Immune globulin may be administered with the vaccine (at a different injection site) to patients requiring immediate prophylaxis or postexposure

Havrix 1440 sollte während der Schwangerschaft nur nach sorgfältiger Abwägung des Nutzen-Risiko-Verhältnisses verabreicht werden, wenn die Impfung eindeutig erforderlich ist. Stillzeit. Es sind keine geeigneten Daten zur Anwendung von Havrix 1440 bei Frauen während der Stillzeit sowie geeignete tierexperimentelle Studien zur

Havrix 1440 Adulto é uma vacina que protege contra a doença causada pelo vírus da hepatite A (VHA). Destina-se a indivíduos adultos e adolescentes a partir dos 16 anos de idade, inclusive. A vacina atua obrigando o organismo a produzir as suas próprias defesas (anticorpos) contra esta doença.

For Product Information and Consumer Medicine Information about Havrix 1440 visit the Therapeutic Goods Administration website. Additional vaccine information For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.

Havrix 1440 is verkrijgbaar in een voorgevulde spuit met of zonder naalden met 1 dosis, verpakkingsgrootten van 1, 5, 10, en Het is mogelijk dat niet alle genoemde verpakkingsgrootten in de handel worden gebracht. Houder van de vergunning voor het in de handel brengen en fabrikant

Havrix 1440 sollte während der Schwangerschaft nur nach sorgfältiger Abwägung des Nutzen-Risiko-Verhältnisses verabreicht werden, wenn die Impfung eindeutig erforderlich ist. Stillzeit. Es sind keine geeigneten Daten zur Anwendung von Havrix 1440 bei Frauen während der Stillzeit sowie geeignete tierexperimentelle Studien zur Havrix 1440 Adulto é uma vacina que protege contra a doença causada pelo vírus da hepatite A (VHA). Destina-se a indivíduos adultos e adolescentes a partir dos 16 anos de idade, inclusive. A vacina atua obrigando o organismo a produzir as suas próprias defesas (anticorpos) contra esta doença.

For Product Information and Consumer Medicine Information about Havrix 1440 visit the Therapeutic Goods Administration website. Additional vaccine information For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s. Havrix 1440 is verkrijgbaar in een voorgevulde spuit met of zonder naalden met 1 dosis, verpakkingsgrootten van 1, 5, 10, en Het is mogelijk dat niet alle genoemde verpakkingsgrootten in de handel worden gebracht. Houder van de vergunning voor het in de handel brengen en fabrikant

Hepatitis A Havrix 1440 Havrix 720 Ab 15 J. 1-14 J. 1 x Nein > 2 Wochen 95% 1 x nach 6 Monaten, für vermutlich lebenslangen Schutz Havrix/Vaqta zur Auffrischung austauschbar Schwangere/Stillende nach Nutzen-Risiko- Abwägung mög-lich Vaqta 50 Vaqta 25 Kind Ab 18 J. 1-17 J. 1 x Nein > 4 Wochen 99%, vermutlich früher 95% Hepatitis B Engerix B Erw.

Of solicited adverse reactions in clinical trials of adults, who received HAVRIX 1440 EL.U., and children (aged 2 years and older), who received either HAVRIX 360 EL.U. or 720 EL.U., the

Havrix 1440 je registrovaný léčivý přípravek - vakcína. Obsahuje virus hepatitis A inactivatum. Přípravek je vázán na lékařský předpis. O očkování se předem poraďte s lékařem a pečlivě si pročtěte příbalovou informaci. Očkování nemusí ochránit 100 % očkovaných osob.

Of solicited adverse reactions in clinical trials of adults, who received HAVRIX 1440 EL.U., and children (aged 2 years and older), who received either HAVRIX 360 EL.U. or 720 EL.U., the most frequently reported was injection-site soreness (56% of adults and 21% of children); less than 0.5% of soreness was reported as severe.

Havrix Vaccine: Package Insert / Prescribing Information - Drugs.com

Hepatitis A Havrix 1440 Havrix 720 Ab 15 J. 1-14 J. 1 x Nein > 2 Wochen 95% 1 x nach 6 Monaten, für vermutlich lebenslangen Schutz Havrix/Vaqta zur Auffrischung austauschbar Schwangere/Stillende nach Nutzen-Risiko- Abwägung mög-lich Vaqta 50 Vaqta 25 Kind Ab 18 J. 1-17 J. 1 x Nein > 4 Wochen 99%, vermutlich früher 95% Hepatitis B Engerix B Erw.

Of solicited adverse reactions in clinical trials of adults, who received HAVRIX 1440 EL.U., and children (aged 2 years and older), who received either HAVRIX 360 EL.U. or 720 EL.U., the Havrix 1440 je registrovaný léčivý přípravek - vakcína. Obsahuje virus hepatitis A inactivatum. Přípravek je vázán na lékařský předpis. O očkování se předem poraďte s lékařem a pečlivě si pročtěte příbalovou informaci.

Očkování nemusí ochránit 100 % očkovaných osob. Of solicited adverse reactions in clinical trials of adults, who received HAVRIX 1440 EL.U., and children (aged 2 years and older), who received either HAVRIX 360 EL.U. or 720 EL.U., the most frequently reported was injection-site soreness (56% of adults and 21% of children); less than 0.5% of soreness was reported as severe.

HAVRIX 1440 U/1 mL ADULTES n'a aucun effet ou qu'un effet négligeable sur l'aptitude à conduire des véhicules et à utiliser des machines. HAVRIX 1440 U/1 mL ADULTES contient de la phénylalanine, du polysorbate H20, du sodium et du potassium. Ce vaccin contient 0,166 mg de phénylalanine par dose.

A single dose of Havrix 1440 (1 mL) is used for primary immunisation. To prolong the protective effect, a single booster dose of Havrix 1440 is recommended at any time between 6 and 12 months after the primary dose. Long-term persistence of serum antibodies after vaccination with Havrix is under evaluation.

Havrix is a vaccine used to prevent hepatitis A infection. The virus particles it contains are inactive but stimulate Hepatitis A antibody production. It comes in two strengths: Havrix 1440 for adults and children aged 16 years and over; and Havrix Junior for children aged 2 to 15 years.

Immunogenicity of HAVRIX was studied in subjects with chronic liver disease of various etiologies. 189 healthy adults and 220 adults with either chronic hepatitis B (n = 46), chronic hepatitis C (n = 104), or moderate chronic liver disease of other etiology (n = 70) were vaccinated with HAVRIX 1440 EL.U. on a 0- and 6-month schedule.

HAVRIX- hepatitis a vaccine injection, suspension - DailyMed

HAVRIX 1440 U/1 mL ADULTES n'a aucun effet ou qu'un effet négligeable sur l'aptitude à conduire des véhicules et à utiliser des machines. HAVRIX 1440 U/1 mL ADULTES contient de la phénylalanine, du polysorbate H20, du sodium et du potassium. Ce vaccin contient 0,166 mg de phénylalanine par dose. A single dose of Havrix 1440 (1 mL) is used for primary immunisation. To prolong the protective effect, a single booster dose of Havrix 1440 is recommended at any time between 6 and 12 months after the primary dose.

Long-term persistence of serum antibodies after vaccination with Havrix is under evaluation. Havrix is a vaccine used to prevent hepatitis A infection. The virus particles it contains are inactive but stimulate Hepatitis A antibody production. It comes in two strengths: Havrix 1440 for adults and children aged 16 years and over; and Havrix Junior for children aged 2 to 15 years. Immunogenicity of HAVRIX was studied in subjects with chronic liver disease of various etiologies.

189 healthy adults and 220 adults with either chronic hepatitis B (n = 46), chronic hepatitis C (n = 104), or moderate chronic liver disease of other etiology (n = 70) were vaccinated with HAVRIX 1440 EL.U. on a 0- and 6-month schedule.

Havrix 1440 ist ein Impfstoff, der bei Erwachsenen und Jugendlichen ab dem Lebensjahr angewendet wird, um eine Hepatitis A-Erkrankung zu vermeiden. Der Impfstoff wirkt, indem er die Bildung von Antikörpern gegen diesen Virus anregt.

In a subset of vaccinees (n = 89), a single dose of Havrix 1440 EL.U. elicited specific anti-HAV neutralizing antibodies in more than 94% of vaccinees when measured 1 month after vaccination

For Product Information and Consumer Medicine Information about Havrix 1440 visit the Therapeutic Goods Administration website. Additional vaccine information For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.

Gegenanzeigen von HAVRIX 1440 Impfdosis Inj.-Susp.i.e.Fertigspritze. Beschreibt, welche Erkrankungen oder Umstände gegen eine Anwendung des Arzneimittels sprechen, in welchen Altersgruppen das Arzneimittel nicht eingesetzt werden sollte/darf und ob Schwangerschaft und Stillzeit gegen die Anwendung des Arzneimittels sprechen.

HAVRIX 1440 Impfdosis Inj.-Susp.i.e.Fertigspritze - Beipackzettel

Havrix 1440 ist ein Impfstoff, der bei Erwachsenen und Jugendlichen ab dem Lebensjahr angewendet wird, um eine Hepatitis A-Erkrankung zu vermeiden. Der Impfstoff wirkt, indem er die Bildung von Antikörpern gegen diesen Virus anregt. In a subset of vaccinees (n = 89), a single dose of Havrix 1440 EL.U. elicited specific anti-HAV neutralizing antibodies in more than 94% of vaccinees when measured 1 month after vaccination For Product Information and Consumer Medicine Information about Havrix 1440 visit the Therapeutic Goods Administration website. Additional vaccine information For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.

Gegenanzeigen von HAVRIX 1440 Impfdosis Inj.-Susp.i.e.Fertigspritze. Beschreibt, welche Erkrankungen oder Umstände gegen eine Anwendung des Arzneimittels sprechen, in welchen Altersgruppen das Arzneimittel nicht eingesetzt werden sollte/darf und ob Schwangerschaft und Stillzeit gegen die Anwendung des Arzneimittels sprechen.

HAVRIX 1440 Dosis adulta obsahuje fenylalanín, sodík a draslík Táto očkovacia látka obsahuje 0,166 mg fenylalanínu v každej dávke. Fenylalanín môže byť škodlivý, ak máte fenylketonúriu (phenylketonuria, PKU), zriedkavú genetickú poruchu, pri ktorej sa hromadí fenylalanín, pretože telo ho nevie správne odstrániť.

Havrix 1440 Adult zawiera 166 mikrogramów fenyloalaniny w każdej dawce. Fenyloalanina może być szkodliwa dla pacjentów z fenyloketonurią. Ta szczepionka zawiera mniej niż 1 mmol (23 mg) sodu na dawkę, to znaczy szczepionkę uznaje się za „wolną od sodu".

Havrix (≥ 16 jaar): een dosis van 1440 E i.m. en na 6-12 maanden nogmaals een dosis van 1440 E. Vaqta Adult (≥ 18 jaar): een dosis van 50 E i.m. en na 6-12 maanden nogmaals een dosis van 50 E; bij HIV-geïnfecteerde volwassenen na 6 maanden de tweede dosis toedienen. Kinderen

2 - Children and adolescents from 1 year up to and including 18 years of age . A single dose of 720 Junior (0.5 mHAVRIX L suspension) is used for primary immunisation. • Booster vaccination After primary vaccination with either 1440 Adult or HAVRIX HAVRIX 720 Junior, a booster dose is recommended in order to ensure long term protection.

PDF HAVRIX 1440 (ADULT) / 720 (JUNIOR) Inactivated Hepatitis A - GSK

HAVRIX 1440 Dosis adulta obsahuje fenylalanín, sodík a draslík Táto očkovacia látka obsahuje 0,166 mg fenylalanínu v každej dávke. Fenylalanín môže byť škodlivý, ak máte fenylketonúriu (phenylketonuria, PKU), zriedkavú genetickú poruchu, pri ktorej sa hromadí fenylalanín, pretože telo ho nevie správne odstrániť. Havrix 1440 Adult zawiera 166 mikrogramów fenyloalaniny w każdej dawce. Fenyloalanina może być szkodliwa dla pacjentów z fenyloketonurią. Ta szczepionka zawiera mniej niż 1 mmol (23 mg) sodu na dawkę, to znaczy szczepionkę uznaje się za „wolną od sodu".

Havrix (≥ 16 jaar): een dosis van 1440 E i.m. en na 6-12 maanden nogmaals een dosis van 1440 E. Vaqta Adult (≥ 18 jaar): een dosis van 50 E i.m. en na 6-12 maanden nogmaals een dosis van 50 E; bij HIV-geïnfecteerde volwassenen na 6 maanden de tweede dosis toedienen. Kinderen 2 - Children and adolescents from 1 year up to and including 18 years of age .

A single dose of 720 Junior (0.5 mHAVRIX L suspension) is used for primary immunisation. • Booster vaccination After primary vaccination with either 1440 Adult or HAVRIX HAVRIX 720 Junior, a booster dose is recommended in order to ensure long term protection.

Of solicited adverse reactions in clinical trials of adults, who received HAVRIX 1440 EL.U., and children (aged 2 years and older), who received either HAVRIX 360 EL.U. or 720 EL.U., the most frequently reported was injection-site soreness (56% of adults and 21% of children); less than 0.5% of soreness was reported as severe.

Havrix 720 Junior (0,5 ml suspensión) se debe administrar por vía intramuscular en la región deltoidea en niños y adolescentes, y en la parte anterolateral del muslo en niños pequeños si el músculo deltoides aún no está lo suficientemente desarrollado (ver sección 6.6). Havrix 1440 Adulto (1,0 ml suspensión) se debe administrar por vía intramuscular en la región deltoidea en

HAVRIX (hepatitis A vaccine, inactivated) is available as HAVRIX 1440 (1440 ELISA Units/mL) and HAVRIX 720 Junior (720 ELISA Units/0.5 mL) suspension for injection. Composition HAVRIX is a sterile suspension containing formaldehyde-inactivated hepatitis A virus (HM175 hepatitis A virus strain) adsorbed onto aluminium hydroxide.

Havrix: 1 mL IM followed by a 1 mL booster dose 6 to 12 months following primary immunization. Primary immunization is recommended at least 2 weeks before expected exposure to hepatitis A virus. Immune globulin may be administered with the vaccine (at a different injection site) to patients requiring immediate prophylaxis or postexposure